Riskpilot← Back to searchSign inGet full accessEques indolor AB
ABActiveOrg 5566637939Kungsholmstorg 6 SmärtklinikenMedical specialists activities · NACE 8622Est. 20043 employees
Revenue 2025
SEK 9,3M
+32% vs 2024
EBITDA margin
23.2%
+203% vs 2024
Equity ratio
42.6%
Financial strength
Net profit 2025
SEK 1,3M
+196% vs 2024
| Revenue | SEK 9,3M | +32% |
| EBITDA | SEK 2,2M | +203% |
| Net profit | SEK 1,3M | +196% |
| Total assets | SEK 3,2M | +33% |
| Equity | SEK 1,4M | +157% |
| Employees | 3 | — |
Legal name
Eques indolor AB
Org number
5566637939
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
2 juli 2004
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva kursverksamhet, datakonsultverksamhet, hälso- och sjukvård, rehabilitering samt idka därmed förenlig verksamhet.
Address
Kungsholmstorg 6 Smärtkliniken
Phone
+468236500
Email
johan@smartkliniken.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 834 | 8 821 | 7 891 | 7 043 | 9 262 |
| Staff expenses | — | −4 174 | −4 037 | −3 637 | −2 934 |
| EBITDA | 2 014 | 1 082 | 1 275 | 709 | 2 151 |
| Depreciation & amort. | −435 | −374 | −213 | −64 | −11 |
| EBIT | 1 579 | 707 | 1 062 | 645 | 2 139 |
| Net financials | −1 | −1 | −2 | 9 | 17 |
| Profit before tax | 1 622 | 726 | 1 064 | 591 | 1 610 |
| Tax | −348 | −151 | −220 | −159 | −332 |
| Net profit | 1 274 | 575 | 844 | 432 | 1 278 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 650 | 2 091 | 2 373 | 2 435 | 3 239 |
| Equity | 1 385 | 710 | 954 | 535 | 1 378 |
| Long-term debt | 166 | 180 | 497 | 873 | 260 |
| Short-term debt | 917 | 1 040 | 765 | 806 | 832 |
| Total debt | 1 083 | 1 220 | 1 262 | 1 678 | 1 093 |
EBITDA margin
23.2%
This company
15.8%
Market median
+47% vs market
20212025
Equity ratio
42.6%
This company
38.2%
Market median
+12% vs market
20212025
Return on equity
92.7%
This company
18.4%
Market median
+404% vs market
20212025
Net profit margin
13.8%
This company
8.1%
Market median
+70% vs market
20212025
Asset turnover
2.86×
This company
1.12×
Market median
+155% vs market
20212025
Debt / equity
1.35×
This company
0.62×
Market median
-118% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EL Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
LI Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Eques indolor AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Ida Maria Ulfhielm | Chief Auditor | 0 companies |
| Eva Louise Desirée Ljung | Chief Auditor | 0 companies |
| Johan Lars Erik Hambraeus | Deputy Board Member | 0 companies |
| Kjerstin E Segerstedt Hambraeus | Deputy Board Member | 0 companies |
| Rolf Johan Tobias Pettersson | Board of Directors | 0 companies |